ViiV Healthcare is an independent, global specialist HIV company established in 2009 with commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS. An essential element of our work is to develop our medicines through conducting clinical trials, where we...
Other key data to be presented from ViiV Healthcare’s innovative pipeline and portfolio include the exploration of different mechanisms of action through broadly neutralising antibodies as well as real-world insights from established long-acting and 2-drug regimens GSK...
ViiV Healthcare and Halozyme Therapeutics have entered a global partnership and licence agreement to leverage the latter’s ENHANZE drug delivery technology to develop ‘ultra long-acting’ drugs for human immunodeficiency virus (HIV). According to the deal, Halozyme will receive an upfront payment...
ViiV Healthcare CEO Deborah Waterhouse said: “Our focus at ViiV Healthcare is on developing innovative medicines not just to treat and cure HIV but to prevent its acquisition. “Today’s announcement marks a critical milestone in our efforts to create a new PrEP option that provides an ...
According to another aspect of the main embodiment, injections must be administered by a healthcare professional. A complete dose requires 2 injections: one injection of cabotegravir and one injection of rilpivirine. Injections of the Combination are intended for intramuscular use only. Consider the ...
Kimberly Smith, MD, Head of Global Research & Medical Strategy at ViiV Healthcare,said: “With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important...
Cabotegravir is an HIV integrase inhibitor, being developed by ViiV Healthcare, as a monotherapy, for the treatment and prevention of HIV infections.
company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visitwww.viivhealthcare.com...
ViiV Healthcare and Janssen have announced the Health Canada approval of Cabenuva as a once-monthly, long-acting therapy for adults with HIV-1 infection.